CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases
CRISPR Therapeutics reported encouraging Phase 1 data for zugo-cel, its wholly-owned CD19-targeting allogeneic CAR-T, in refractory rheumatologic autoimmune diseases at ACR Convergence 2026. In the systemic sclerosis cohort, 83% of patients (5/6) on standard lymphodepletion achieved an rCRISS-25 response at Month 3, with all responders maintaining response; all nine IIM patients achieved a moderate or major TIS response. Zugo-cel has been well tolerated across all 21 dosed patients, with no CRS above Grade 2, no ICANS or IEC-HS, and no deaths.
Key figures
- Drug Name
- zugocabtagene geleucel (zugo-cel; formerly CTX112)
- Phase Of Trial
- Phase 1
- Patients dosed
- 21
- Iim tis response
- 9/9 moderate or major response
- Ssc response rate
- 83% (5/6) rCRISS-25 at Month 3 with standard lymphodepletion
- Sle doris remission
- 2/3 evaluable patients in drug-free remission through at least Month 9
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.